<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630069</url>
  </required_header>
  <id_info>
    <org_study_id>NIH_ATS</org_study_id>
    <nct_id>NCT02630069</nct_id>
  </id_info>
  <brief_title>CDP-choline Treatment in ATS Users</brief_title>
  <official_title>Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University Mokdong Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 12-week, randomized, double-blind, placebo-controlled trial of
      cytidine-5'-diphosphate choline in amphetamine-type stimulants-using adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 12-week, randomized, double-blind, placebo-controlled trial of
      cytidine-5'-diphosphate choline (CDP-choline) in amphetamine-type stimulants-using
      adolescents. Multi-level assessments will be performed to determine whether CDP-choline
      administration with supportive psychotherapy, compared to placebo administration with
      supportive psychotherapy, will 1) repair ATS-induced neural cell damage of the target brain
      regions, 2) improve cognitive deficits and normalize the relevant target neural circuits, and
      then 3) reduce ATS-taking behaviors in ATS-using adolescents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the total number of amphetamine- and methamphetamine(MA)-negative samples using urine screening</measure>
    <time_frame>baseline through 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>abstinence which is defined as five or more consecutive weeks of amphetamine- and MA-negative samples</measure>
    <time_frame>baseline through 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment program retention</measure>
    <time_frame>baseline through 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>standardized scores on a neuropsychological test battery</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural brain changes in magnetic resonance imaging assessed by computational approaches</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional brain changes in magnetic resonance imaging assessed by computational approaches</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic brain changes in magnetic resonance imaging assessed by computational approaches</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>CDP-choline+supportive psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+supportive psychotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP-choline</intervention_name>
    <description>CDP-choline 500mg once a day for 12 weeks</description>
    <arm_group_label>CDP-choline+supportive psychotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 500mg once a day for 12 weeks</description>
    <arm_group_label>Placebo+supportive psychotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supportive psychotherapy</intervention_name>
    <description>Supportive psychotherapy 1 session/2 weeks for 12 weeks</description>
    <arm_group_label>CDP-choline+supportive psychotherapy</arm_group_label>
    <arm_group_label>Placebo+supportive psychotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 14-40 years

          -  Amphetamine (or amphetamine-like) use disorder (DSM-IV-TR)

          -  Informed consent

          -  Seeking treatment

        Exclusion Criteria:

          -  Major medical or neurological illnesses

          -  Psychiatric illnesses requiring hospitalization, prescription of psychotropic
             medications, or emergency psychiatric interventions

          -  Current and past diagnosis of a psychotic disorder, bipolar disorder, conduct
             disorder, or attention-deficit hyperactivity disorder

          -  Occasional ATS use (less than monthly use)

          -  IQ of 80 or lower

          -  Pregnancy or breastfeeding

          -  Clinically significant suicidal or homicidal ideation

          -  Substance use disorders (substances other than amphetamine or MA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sujung Yoon, MD, PhD</last_name>
    <phone>82-2-3277-2478</phone>
    <email>sujungjyoon@ewha.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Hui Kim, BSN, RN</last_name>
      <phone>82-2-2650-2812</phone>
      <email>ewhactc@nate.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University Mokdong Hospital</investigator_affiliation>
    <investigator_full_name>Sujung Yoon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>amphetamine type stimulant</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

